Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.(Image credit: Fred Tanneau)

Kalshi and Polymarket say allowing people to bet on the outcomes of clinical trials and FDA drug approvals provides valuable information about drug development. But researchers warn the bets could incentivize insider trading and interfere with the integrity of the process.

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

(Image credit: Fred Tanneau)

Source: NPR Topics: News

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending now

Egestas Egestas Fringilla Phasellus Faucibus Scelerisque
Palantir Popped 39% This Week, Leads 27 To Best Stock Lists
Enim Facilisis Gravida Neque Convallis Cras Semper Auctor
Fermentum Dui Faucibus Bnornare Quam Viverra Orci